Are Peptides Safe? What Consumers Need to Know About FDA Approval, Compounding and Health Risks

Peptides are becoming increasingly popular in the wellness and “biohacking” markets, with public figures including Secretary of Health and Human Services Robert F. Kennedy Jr. helping bring attention to the trend.

Some peptide-based medicines, including insulin and GLP-1 drugs such as Ozempic and Wegovy, have been rigorously tested and approved by the Food and Drug Administration (FDA). However, many other peptides sold online remain unapproved, untested in humans and manufactured by companies that may not follow pharmaceutical safety standards.

This has created a multibillion-dollar gray market for injectable peptides. According to health care safety researchers, some of these products are sold without evidence that they are pure, sterile, effective or safe for human use.

In July 2026, an FDA advisory committee voted to recommend making several unapproved peptides available to compounding pharmacies. The products are marketed for uses including sleep support, wound healing, muscle recovery, cognitive health, inflammation and longevity. The recommendation is not legally binding, and the FDA must complete its formal review and rulemaking process before any policy change becomes final.

So, what does the advisory committee’s recommendation mean for peptide regulation—and what should consumers know about the potential risks? Here is a science-based overview.

What are peptides?

Peptides are short chains of amino acids, the building blocks of proteins. They are generally smaller and less structurally complex than proteins.

The body naturally produces thousands of peptides that act as biological messengers. Some help regulate blood sugar, mood, appetite, inflammation and other functions. Examples include insulin, oxytocin, vasopressin and endorphins. Scientists have identified approximately 7,000 known peptides.

Insulin was the first synthetically produced peptide medicine. It replaces the insulin normally made by the pancreas and is essential for many people with diabetes.

More recently, GLP-1 receptor agonists—including Ozempic, Wegovy and similar medicines—have become widely used for diabetes and weight management. These drugs imitate the naturally occurring GLP-1 hormone, which is produced in the intestine and helps signal to the brain that the body has eaten enough.

Peptide medicines may be injected, taken by mouth or delivered through a nasal spray. Under U.S. law, products intended to treat or prevent disease—or to affect the structure or function of the body—are generally considered drugs and must meet FDA requirements for safety, quality and effectiveness.

Plant- and food-derived products such as collagen peptides are usually sold as dietary supplements. Dietary supplements are regulated less strictly than prescription medicines, so their potency, purity and consistency can vary.

Which peptide uses are supported by scientific evidence?

Approved peptide medicines such as insulin and GLP-1 receptor agonists have undergone clinical testing designed to determine whether they are safe and effective for particular medical conditions. The FDA has approved approximately 100 peptide-based medicines for conditions including diabetes and multiple sclerosis.

Other peptides are promoted for general wellness, muscle growth, injury recovery, anti-aging, cognitive enhancement and “biohacking.” However, many of these products lack high-quality human studies demonstrating that they work or establishing safe doses.

Some unapproved peptides are labeled “for research use only.” This wording is not evidence that a product is safe for people. In some cases, products carrying the label have still been advertised and sold for human use, despite the lack of FDA approval and clinical testing.

“Many other peptides have not yet received FDA approval and should be considered experimental,” Long told Live Science.

How is peptide regulation changing in the United States?

At a July 2026 meeting, an FDA advisory committee discussed seven unapproved peptides and voted to recommend increased access to six of them through compounding pharmacies.

Compounding pharmacies prepare customized medicines for individual patients. They operate under different requirements from manufacturers of FDA-approved drugs, and some compounded medicines may contain active ingredients that have not been approved by the FDA. The FDA has stated that compounded drugs are not the same as FDA-approved medicines and are not reviewed for safety, effectiveness or quality before they reach patients.

The committee’s vote was a recommendation rather than a final regulatory decision. The FDA must still determine whether to accept the recommendation and complete any required rulemaking.

Some researchers have described the proposal as a potential shift in U.S. peptide policy. The FDA previously placed several of these substances on a list of bulk drug substances that may present safety risks when used in compounding. Critics argue that unapproved peptides should not be made more widely available without stronger evidence from human clinical trials.

According to Dr. Katrin Svensson, an associate professor and peptide researcher at Stanford University, some of the compounds have not been tested in humans and have little supporting evidence from laboratory or animal studies.

The advisory committee’s membership has also drawn scrutiny because several members were appointed by Kennedy and some have ties to the peptide industry. Although advisory recommendations are not binding, public health experts say broader access could increase consumer use of unapproved products and make it more difficult to distinguish experimental compounds from evidence-based treatments.

What scientific evidence supports the proposed change?

Researchers interviewed by Live Science said the advisory committee’s recommendation was not based on new evidence showing that the peptides are safer or more effective.

“This decision does not say that these peptides are more scientifically valid or that they are safer or more effective,” Long said. “The main effect of the vote could be to allow more people to access these peptides through compounding pharmacies.”

Svensson similarly said the policy discussion is moving faster than the science. Without well-designed human trials, researchers may not know the appropriate dose, potential side effects, long-term risks or whether the compounds provide meaningful health benefits.

Could broader peptide access help or harm consumers?

Supporters of compounding argue that products prepared by a reputable pharmacy may be purer and more consistently manufactured than substances purchased from unregulated online sellers. Properly prepared medicines should also be sterile and contain the labeled ingredient.

However, improved manufacturing quality does not make an unapproved peptide safe or effective. A sterile vial can still contain a compound that has not been adequately studied in humans, has an unknown dose or interacts dangerously with other medicines.

“Getting the peptide from a compounding pharmacy means the peptide in the vial may be pure and the vial may be sterile,” Long said. “However, this does not mean that these peptides are safe for use in humans or that they can treat every condition for which they are marketed.”

Svensson cautioned that peptides range from well-established pharmaceuticals to experimental compounds with limited evidence.

“Easier access does not lower the evidentiary bar,” she said. “Clinical trials are still needed to determine whether these products are useful.”

What should consumers know before using peptides?

Consumers should not assume that a peptide is safe simply because it is sold online, prescribed by a wellness provider or prepared by a compounding pharmacy. “Allowed for compounding” does not mean “FDA approved.”

Before considering any peptide product, consumers should:

• Ask whether the product is FDA approved for the intended use.
• Discuss the treatment with a licensed health care professional.
• Confirm the source, storage conditions and labeling of any compounded medicine.
• Ask about possible side effects and interactions with existing medications.
• Avoid products labeled “for research use only” that are marketed for human consumption.
• Be cautious of claims involving rapid weight loss, anti-aging, muscle growth, injury recovery or life extension without strong clinical evidence.

For many wellness peptides, human evidence remains limited, recommended doses are uncertain and long-term safety has not been established. Products purchased from unregulated sources may also be contaminated, incorrectly labeled or significantly different from what is listed on the packaging.

“I personally would not inject myself with an experimental molecule,” Long said.